SCHEMBL23218438

SCHEMBL23218438

O=CCc1cc(Br)c2occc2c1F

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23219171 0.81 HTR2A (0.33)
SCHEMBL21437650 0.80 HTR2A (0.33)
SCHEMBL23218844 0.77 HTR2C (0.30)
SCHEMBL23218095 0.76 PTPN1 (0.43) PTPN1
SCHEMBL29853187 0.76 PTPN1 (0.43) PTPN1
SCHEMBL4992632 0.73 GYS1 (0.30)
SCHEMBL26475950 0.72 PTPN1 (0.34) PTPN1
SCHEMBL24199941 0.71 KCNA2 (0.30)
SCHEMBL6305380 0.70 HTR2A (0.32)
SCHEMBL23218572 0.70 NPC1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed